Softhale N.V.

Our acquisition

Softhale N.V.

Our acquisition

Softhale N.V.


Softhale N.V. (Softhale) is a wholly owned subsidiary of invoX. It is a Belgian-based respiratory company focused on the development of pharmaceutical products delivered by their SMI device to the lungs.

Technology

Softhale is developing liquid-based, Soft Mist Inhaled (“SMI”) products with superior clinical performance based upon differentiated technology. A proprietary, propellant-free, purely mechanical device delivers medication to the lungs more effectively than other types of inhalers and in large markets including Asthma, COPD, and other lung indications.

Founders & Team

The founders out of Germany met in 2012 and started their conceptual work on a new generation Soft Mist Inhaler (SMI) which resulted in their 1st patent in 2013. Over the years the team grew with profound medical, pharmaceutical / chemical, medical device, and consumer products expertise.

Acquisition

On 22 March 2021, invoX entered into an agreement in relation to a 100% acquisition of Softhale.

invoX vision on Softhale

The following strategic significance is considered by the Board:

  1. Solidifies the Group’s leading position in the respiratory therapeutic area by offering the next general inhaler technology.
  2. Enhances the Group’s transformation from generics to innovation player by acquiring and fully controlling its own respiratory R&D capability.
  3. Accelerates the Group’s internationalization strategy by establishing a local hub in Europe as well as developing products with significant global market potential
Visit Softhale website